Literature DB >> 33686024

Preclinical systematic review of ginsenoside Rg1 for cognitive impairment in Alzheimer's disease.

Hai-Yong Liang1, Pei-Pei Zhang1, Xi-Le Zhang1, Yan-Yan Zheng1, Yan-Ran Huang1, Guo-Qing Zheng1, Yan Lin1.   

Abstract

Ginseng has been used for the treatment of aging and memory impairment for thousands of years. Several studies have found that ginsenoside Rg1, as one of the main active components of ginseng, could potentially improve cognitive function in several different animal models. A preclinical systematic review to evaluate the efficacy and mechanisms of ginsenoside Rg1 for ameliorating cognitive impairments in Alzheimer's disease is reported here. We searched six databases from their inceptions to January 2019. Thirty-two studies were selected, which included a total of 1,643 animals. According to various cognitive behavioral tests, the results of the meta-analyses showed that ginsenoside Rg1 significantly improved cognitive behavioral impairments in most Alzheimer's disease models (P < 0.05), but there were no significant effects in animals with neuronal degeneration induced by chronic stress or in SAMP8 transgenic mice. The potential mechanisms included antioxidant and anti-inflammatory effects, amelioration of Alzheimer's disease-related pathology, synapse protection, and up-regulation of nerve cells via multiple signaling pathways.

Entities:  

Keywords:  Alzheimer's disease; ginsenoside Rg1; learning and memory; potential mechanisms; preclinical evidence

Year:  2021        PMID: 33686024      PMCID: PMC7993717          DOI: 10.18632/aging.202619

Source DB:  PubMed          Journal:  Aging (Albany NY)        ISSN: 1945-4589            Impact factor:   5.682


  87 in total

1.  Methodological and Reporting Errors in Meta-Analytic Reviews Make Other Meta-Analysts Angry: A Commentary on Ferguson (2015).

Authors:  Hannah R Rothstein; Brad J Bushman
Journal:  Perspect Psychol Sci       Date:  2015-09

Review 2.  Role of cholinesterase inhibitors in dementia care needs rethinking.

Authors:  Anthony J Pelosi; Seamus V McNulty; Graham A Jackson
Journal:  BMJ       Date:  2006-09-02

3.  Pharmacotherapy for Dementia: A Practical Approach to the Use of Cholinesterase Inhibitors and Memantine.

Authors:  Chit Wai Wong
Journal:  Drugs Aging       Date:  2016-07       Impact factor: 3.923

Review 4.  Donepezil across the spectrum of Alzheimer's disease: dose optimization and clinical relevance.

Authors:  J-H Lee; S-K Jeong; B C Kim; K W Park; A Dash
Journal:  Acta Neurol Scand       Date:  2015-02-18       Impact factor: 3.209

Review 5.  A systematic review comparing sex differences in cognitive function in schizophrenia and in rodent models for schizophrenia, implications for improved therapeutic strategies.

Authors:  Marianne Leger; Joanna C Neill
Journal:  Neurosci Biobehav Rev       Date:  2016-06-22       Impact factor: 8.989

6.  Ginsenoside Rd promotes non-amyloidogenic pathway of amyloid precursor protein processing by regulating phosphorylation of estrogen receptor alpha.

Authors:  Xiaodong Yan; Gengyao Hu; Weiming Yan; Tao Chen; Feng Yang; Xiao Zhang; Gang Zhao; Juanfang Liu
Journal:  Life Sci       Date:  2016-11-04       Impact factor: 5.037

Review 7.  Opportunities and challenges in developing relevant animal models for Alzheimer's disease.

Authors:  Fernanda G De Felice; Douglas P Munoz
Journal:  Ageing Res Rev       Date:  2016-01-30       Impact factor: 10.895

Review 8.  Pharmacological and medical applications of Panax ginseng and ginsenosides: a review for use in cardiovascular diseases.

Authors:  Jong-Hoon Kim
Journal:  J Ginseng Res       Date:  2017-10-21       Impact factor: 6.060

9.  Ginsenoside Rg1 decreases Aβ(1-42) level by upregulating PPARγ and IDE expression in the hippocampus of a rat model of Alzheimer's disease.

Authors:  QianKun Quan; Jue Wang; Xi Li; Yi Wang
Journal:  PLoS One       Date:  2013-03-08       Impact factor: 3.240

10.  Two years later: journals are not yet enforcing the ARRIVE guidelines on reporting standards for pre-clinical animal studies.

Authors:  David Baker; Katie Lidster; Ana Sottomayor; Sandra Amor
Journal:  PLoS Biol       Date:  2014-01-07       Impact factor: 8.029

View more
  6 in total

1.  Medication Rules in Herbal Medicine for Mild Cognitive Impairment: A Network Pharmacology and Data Mining Study.

Authors:  Z Chang; Yu-Chun Wang; Danfeng Tian; Wen-Yue Hu; Zhen-Yi Wang; Gan-Lu Liu; Hua-Ping Ma; Yu-Li Hu; Bin Wu; Zhen-Yun Han
Journal:  Evid Based Complement Alternat Med       Date:  2022-05-18       Impact factor: 2.650

2.  Ginsenoside Rg1 Prevents Cognitive Impairment and Hippocampal Neuronal Apoptosis in Experimental Vascular Dementia Mice by Promoting GPR30 Expression.

Authors:  Fengming Shen; Juan Wang; Feng Gao; Jingji Wang; Guoqi Zhu
Journal:  Neural Plast       Date:  2021-12-03       Impact factor: 3.599

3.  Mechanism of Neural Regeneration Induced by Natural Product LY01 in the 5×FAD Mouse Model of Alzheimer's Disease.

Authors:  Xiao-Wan Li; Yang-Yang Lu; Shu-Yao Zhang; Ning-Ning Sai; Yu-Yan Fan; Yong Cheng; Qing-Shan Liu
Journal:  Front Pharmacol       Date:  2022-06-22       Impact factor: 5.988

4.  Yuan-Zhi decoction in the treatment of Alzheimer's disease: An integrated approach based on chemical profiling, network pharmacology, molecular docking and experimental evaluation.

Authors:  Qiong Wu; Xiang Li; Xiao-Wen Jiang; Dong Yao; Li-Jun Zhou; Zi-Hua Xu; Nan Wang; Qing-Chun Zhao; Zhou Zhang
Journal:  Front Pharmacol       Date:  2022-08-24       Impact factor: 5.988

Review 5.  Natural Antioxidant Compounds as Potential Pharmaceutical Tools against Neurodegenerative Diseases.

Authors:  Attilio Marino; Matteo Battaglini; Nadia Moles; Gianni Ciofani
Journal:  ACS Omega       Date:  2022-07-19

Review 6.  New Therapeutic Approaches to and Mechanisms of Ginsenoside Rg1 against Neurological Diseases.

Authors:  Yang Sun; Yantao Yang; Shasha Liu; Songwei Yang; Chen Chen; Meiyu Lin; Qi Zeng; Junpeng Long; Jiao Yao; Fan Yi; Lei Meng; Qidi Ai; Naihong Chen
Journal:  Cells       Date:  2022-08-16       Impact factor: 7.666

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.